CASI Pharmaceuticals Inc. (CASIF) vs Pluri Inc. (PLUR)
CASI Pharmaceuticals Inc. and Pluri Inc. are both Biotechnology companies. CASI Pharmaceuticals Inc. and Pluri Inc. are of similar size ($13.0M and $12.4M). Pluri Inc. grew revenue faster over the last twelve months: −24.0% against −27.4%. CASI Pharmaceuticals Inc. has the higher net margin (−232.0% vs −2,344.6%) and the higher return on invested capital (0.00% vs −526.9%). Across the 17 metrics below, Pluri Inc. leads on 9 and CASI Pharmaceuticals Inc. on 8.
Valuation
Profitability
| Metric | CASIF | PLUR | Biotechnology median |
|---|---|---|---|
| Gross margin | 48.65% | 44.59% | 65.16% |
| Operating margin | (206.87%) | (2,454.53%) | 0.00% |
| Net margin | (232.03%) | (2,344.59%) | 0.00% |
| Free cash flow margin | (432.54%) | (1,988.48%) | 0.00% |
| Return on equity | 0.00% | 260.35% | (57.72%) |
| Return on assets | 0.00% | (74.95%) | (49.22%) |
| Return on invested capital | 0.00% | (526.92%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack